U.S. Markets close in 1 hr 41 mins

Maravai LifeSciences Holdings, Inc. (MRVI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.63+0.48 (+1.71%)
As of 2:19PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close28.15
Open28.29
Bid28.83 x 800
Ask28.96 x 1100
Day's Range28.25 - 30.20
52 Week Range25.56 - 32.46
Volume850,246
Avg. Volume6,032,133
Market Cap7.64B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    GlobeNewswire

    Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters’ option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai’s Class A common stock began trading on the Nasdaq Global Select Market on November 20, 2020 under the symbol "MRVI." Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel and KeyBanc Capital Markets also acted as joint book-running managers, and Academy Securities, Loop Capital Markets, Penserra Securities LLC and Tigress Financial Partners acted as co-managers for the offering.Perella Weinberg Partners L.P. served as capital markets advisor to Maravai. Kirkland & Ellis LLP provided legal counsel to Maravai and Davis Polk & Wardwell LLP provided legal counsel to the underwriters.A registration statement on Form S-1 relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on November 19, 2020. The offering was made only by means of a prospectus. A copy of the final prospectus relating to the securities has been filed with the SEC and may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526, by facsimile at 212-902-9316 or by email at prospectus-ny@ny.email.gs.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. CONTACT: Investor and Media Contact Sara Michelmore MacDougall +1 781-235-3060 maravai@macbiocom.com

  • Sotera Health IPO Prices At High End Of Range; Shares Surge
    Investor's Business Daily

    Sotera Health IPO Prices At High End Of Range; Shares Surge

    Sotera Health raised $1.1 billion with an initial public offering for the provider of medical sterilization, lab testing and advisory services. The Sotera IPO will begin trading Friday.

  • Maravai IPO Raises $1.62 Billion For Provider Of Drug-Testing Services
    Investor's Business Daily

    Maravai IPO Raises $1.62 Billion For Provider Of Drug-Testing Services

    Maravai LifeSciences raised $1.62 billion with an initial public offering for the provider of genetic products and testing services for drug development and research. It trades Friday.